RxDoctor Payments Data

Michael Fine

Laguna Beach, CANPI 1346670007

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $290,583 of the $360,381 with a category attached, or 80.6%. It is spread thinly across 53 manufacturers, the largest accounting for just 12.6%. Reporting peaked in 2019 at $85,096 and has fallen 64.6% since, to $30,105 in 2025.

$360,381in general payments, 2019–2025

Across 265 payments — averaging $1359.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Regeneron Healthcare Solutions, Inc.$46K
  • Sanofi$31K
  • GSK$24K
  • Pfizer$18K
  • Johnson & Johnson$16K
  • Vertex$15K
  • plus $211K from 47 others

What the payments were for

  • Consulting fees$290,58381%
  • Speaking & faculty fees$47,00813%
  • Travel & lodging$20,4306%
  • Food & beverage$2,2931%
  • Education$660%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Where these figures come from

Is this you, or does something look wrong? →